Related Experiment Video
Updated: Oct 17, 2025
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.4K
From Emollients to Biologicals: Targeting Atopic Dermatitis
Lorenzo Salvati1, Lorenzo Cosmi1, Francesco Annunziato1
1Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
International Journal of Molecular Sciences
|October 13, 2021
Summary
Atopic dermatitis (AD) is a common inflammatory skin disease with varied presentations. This review covers AD pathogenesis, current treatments like biologicals, and emerging therapies for better patient outcomes.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin condition.
- Severe AD significantly impairs patients' quality of life.
- AD exhibits diverse clinical phenotypes and endotypes across age groups and ethnicities.
Purpose of the Study:
- To review the current understanding of atopic dermatitis pathogenesis.
- To explore the rationale behind existing atopic dermatitis therapies, from basic emollients to advanced biologicals.
- To introduce novel and promising therapeutic agents for atopic dermatitis management.
Main Methods:
- Literature review of atopic dermatitis pathogenesis.
- Analysis of approved therapeutic strategies for atopic dermatitis.
- Exploration of emerging drug candidates for atopic dermatitis treatment.
Main Results:
- Atopic dermatitis pathogenesis involves complex immune and skin barrier dysfunctions.
- Current therapies, including emollients and biologics, target various aspects of AD.
- Several novel drugs show promise in addressing unmet needs in AD treatment.
Conclusions:
- Understanding AD pathogenesis is crucial for developing effective treatments.
- A range of therapeutic options exists for atopic dermatitis, with ongoing advancements.
- Novel therapies may offer improved efficacy and safety profiles for patients with atopic dermatitis.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
240
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
240
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
686
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
686
01:19Clinical Applications of Epidermal Stem Cells
2.9K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.9K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
259
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
259
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
286
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
286
01:26Targets for Drug Action: Overview
8.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.1K